MedPath

Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Hodgkin's Lymphoma

Phase 3
Conditions
Lymphoma
Registration Number
NCT00041210
Lead Sponsor
Mount Vernon Cancer Centre at Mount Vernon Hospital
Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating patients who have advanced Hodgkin's lymphoma.

PURPOSE: Randomized phase III trial to compare the effectiveness of two different combination chemotherapy regimens in treating patients who have advanced Hodgkin's lymphoma.

Detailed Description

OBJECTIVES:

* Compare relapse-free and overall survival of patients with previously untreated advanced Hodgkin's lymphoma treated with bleomycin, doxorubicin, etoposide, mechlorethamine, vinblastine, vincristine, and prednisone (Stanford V) vs doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD).

* Compare the toxicity of these regimens in these patients.

OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment arms.

* Arm I (Stanford V): Patients receive mechlorethamine on weeks 1, 5, and 9; vinblastine and doxorubicin on weeks 1, 3, 5, 7, 9, and 11; etoposide IV over 30-45 minutes for 2 consecutive days on weeks 3, 7, and 11; and vincristine and bleomycin on weeks 2, 4, 6, 8, 10, and 12. Patients also receive oral prednisone every other day on days 1-63 followed by a taper on days 64-84. Treatment continues for 12 weeks.

* Arm II (ABVD): Patients receive doxorubicin, bleomycin, vinblastine, and dacarbazine on days 1 and 15. Treatment repeats every 28 days for 6-8 courses.

All patients achieving a complete remission or partial remission after chemotherapy undergo involved field radiotherapy if they had initial bulky mediastinal disease, initial nodal masses at least 5 cm in diameter, or initial splenic disease.

Patients are followed every 3 months for 1 year, every 4 months for 1 year, every 6 months for 3 years, and then annually thereafter.

Peer Reviewed and Funded or Endorsed by Cancer Research UK

PROJECTED ACCRUAL: Approximately 700-850 patients will be accrued for this study.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
850
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Relapse-free survival
Secondary Outcome Measures
NameTimeMethod
Overall survival
Toxicity

Trial Locations

Locations (37)

Pinderfields General Hospital

🇬🇧

Wakefield, Scotland, United Kingdom

Aintree University Hospital

🇬🇧

Liverpool, England, United Kingdom

City Hospital - Birmingham

🇬🇧

West Bromwich, England, United Kingdom

New Cross Hospital

🇬🇧

Wolverhampton, England, United Kingdom

Worthing Hospital

🇬🇧

Worthing, England, United Kingdom

Saint Bartholomew's Hospital

🇬🇧

London, England, United Kingdom

Doncaster Royal Infirmary

🇬🇧

Doncaster, England, United Kingdom

Royal Marsden - Surrey

🇬🇧

Sutton, England, United Kingdom

Hull Royal Infirmary

🇬🇧

Hull, England, United Kingdom

Basildon University Hospital

🇬🇧

Basildon, England, United Kingdom

Derriford Hospital

🇬🇧

Plymouth, England, United Kingdom

Velindre Cancer Center at Velindre Hospital

🇬🇧

Cardiff, Wales, United Kingdom

Torbay Hospital

🇬🇧

Torquay, England, United Kingdom

Royal United Hospital

🇬🇧

Bath, England, United Kingdom

Monklands General Hospital

🇬🇧

Airdrie, Scotland, United Kingdom

St. George's Hospital

🇬🇧

London, England, United Kingdom

Portsmouth Oncology Centre at Saint Mary's Hospital

🇬🇧

Portsmouth Hants, England, United Kingdom

Oldchurch Hospital

🇬🇧

Romford, England, United Kingdom

South West Wales Cancer Institute

🇬🇧

Swansea, Wales, United Kingdom

Kent and Canterbury Hospital

🇬🇧

Canterbury, England, United Kingdom

King George Hospital

🇬🇧

Ilford, Essex, England, United Kingdom

James Paget Hospital

🇬🇧

Norfolk, England, United Kingdom

Nottingham City Hospital NHS Trust

🇬🇧

Nottingham, England, United Kingdom

Saint Richards Hospital

🇬🇧

Chichester, England, United Kingdom

Walsgrave Hospital

🇬🇧

Coventry, England, United Kingdom

Hemel Hempstead General

🇬🇧

Hemel Hempstead, England, United Kingdom

Russells Hall Hospital

🇬🇧

Dudley, England, United Kingdom

Royal Devon and Exeter Hospital

🇬🇧

Exeter, England, United Kingdom

Lincoln County Hospital

🇬🇧

Lincoln, England, United Kingdom

University College Hospital - London

🇬🇧

London, England, United Kingdom

Mount Vernon Cancer Centre at Mount Vernon Hospital

🇬🇧

Northwood, England, United Kingdom

Staffordshire General Hospital

🇬🇧

Stafford, England, United Kingdom

Southampton General Hospital

🇬🇧

Southampton, England, United Kingdom

Cancer Research Centre at Weston Park Hospital

🇬🇧

Sheffield, England, United Kingdom

Craigavon Area Hospital

🇬🇧

Craigavon, Northern Ireland, United Kingdom

Cancer Care Centre at York Hospital

🇬🇧

York, England, United Kingdom

Royal Liverpool University Hospital

🇬🇧

Liverpool, England, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath